Bristlecone Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $337K | Buy |
+694
| New | +$323K | 0.03% | 192 |
|
|
2025
Q2 | – | Sell |
-556
| Closed | -$277K | – | 364 |
|
|
2025
Q1 | $277K | Sell |
556
-12
| -2% | -$6.5K | 0.02% | 245 |
|
|
2024
Q4 | $295K | Hold |
568
| – | – | 0.02% | 242 |
|
|
2024
Q3 | $351K | Hold |
568
| – | – | 0.03% | 220 |
|
|
2024
Q2 | $314K | Hold |
568
| – | – | 0.03% | 227 |
|
|
2024
Q1 | $330K | Sell |
568
-10
| -2% | -$5.61K | 0.03% | 222 |
|
|
2023
Q4 | $307K | Sell |
578
-40
| -6% | -$19.4K | 0.03% | 224 |
|
|
2023
Q3 | $313K | Hold |
618
| – | – | 0.04% | 207 |
|
|
2023
Q2 | $322K | Buy |
618
+40
| +7% | +$21.6K | 0.03% | 210 |
|
|
2023
Q1 | $333K | Buy |
578
+50
| +9% | +$28.2K | 0.04% | 209 |
|
|
2022
Q4 | $291K | Buy |
528
+21
| +4% | +$11.1K | 0.04% | 211 |
|
|
2022
Q3 | $257K | Buy |
507
+49
| +11% | +$27.4K | 0.03% | 214 |
|
|
2022
Q2 | $249K | Hold |
458
| – | – | 0.03% | 213 |
|
|
2022
Q1 | $271K | Hold |
458
| – | – | 0.03% | 201 |
|
|
2021
Q4 | $306K | Hold |
458
| – | – | 0.04% | 190 |
|
|
2021
Q3 | $262K | Hold |
458
| – | – | 0.03% | 191 |
|
|
2021
Q2 | $231K | Sell |
458
-10
| -2% | -$4.72K | 0.03% | 202 |
|
|
2021
Q1 | $214K | Sell |
468
-32
| -6% | -$15.3K | 0.03% | 201 |
|
|
2020
Q4 | $233K | Buy |
+500
| New | +$234K | 0.04% | 186 |
|
|
2020
Q1 | – | Sell |
-1,416
| Closed | -$460K | – | 200 |
|
|
2019
Q4 | $460K | Buy |
+1,416
| New | +$429K | 0.09% | 138 |
|
|
2019
Q3 | – | Sell |
-1,248
| Closed | -$367K | – | 178 |
|
|
2019
Q2 | $367K | Buy |
+1,248
| New | +$344K | 0.09% | 140 |
|
|
2018
Q4 | – | Sell |
-1,289
| Closed | -$315K | – | 146 |
|
|
2018
Q3 | $315K | Buy |
1,289
+40
| +3% | +$9.2K | 0.08% | 126 |
|
|
2018
Q2 | $259K | Sell |
1,249
-10
| -0.8% | -$2.12K | 0.09% | 114 |
|
|
2018
Q1 | $260K | Buy |
1,259
+39
| +3% | +$8.19K | 0.09% | 122 |
|
|
2017
Q4 | $232K | Buy |
1,220
+15
| +1% | +$2.87K | 0.07% | 132 |
|
|
2017
Q3 | $228K | Hold |
1,205
| – | – | 0.07% | 133 |
|
|
2017
Q2 | $210K | Buy |
+1,205
| New | +$202K | 0.07% | 141 |
|
|
2017
Q1 | – | Sell |
-1,665
| Closed | -$235K | – | 156 |
|
|
2016
Q4 | $235K | Sell |
1,665
-3,340
| -67% | -$492K | 0.08% | 136 |
|
|
2016
Q3 | $796K | Sell |
5,005
-500
| -9% | -$77K | 0.29% | 88 |
|
|
2016
Q2 | $813K | Sell |
5,505
-215
| -4% | -$31.7K | 0.3% | 82 |
|
|
2016
Q1 | $810K | Buy |
5,720
+2,400
| +72% | +$322K | 0.32% | 78 |
|
|
2015
Q4 | $471K | Buy |
+3,320
| New | +$443K | 0.2% | 112 |
|
Other funds holding TMO
Bristlecone Advisors's TMO Position: Q3 2025 in Review
Bristlecone Advisors opened a new position in Thermo Fisher Scientific (TMO) in Q3 2025: 694 shares worth $337K. The stake represents 0.03% of the portfolio and ranks #192 among its holdings. This is a return to the name: Bristlecone Advisors previously reported a position in TMO as recently as Q1 2025.
Bristlecone Advisors first reported a position in TMO in Q4 2015 and has held it in 32 quarters since. The position peaked at $813K in Q2 2016. 2,508 funds tracked by Wall St. Rank hold TMO as of Q3 2025.
- Bristlecone Advisors held 694 shares of Thermo Fisher Scientific worth $337K as of Q3 2025.
- Thermo Fisher Scientific was a new Bristlecone Advisors position in Q3 2025.
- Thermo Fisher Scientific made up 0.03% of Bristlecone Advisors's portfolio in Q3 2025, its #192 holding.
- Bristlecone Advisors first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 32 quarters since.
- Bristlecone Advisors's Thermo Fisher Scientific position peaked at $813K in Q2 2016.
- 2,508 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.